MD Anderson teams with Eisbach on precision oncology and with Yingli on a five-year translational research effort. Moffitt inks tie-ups with Dyve and Turnstone.

Athenex expands its portfolio of T-cell receptor therapy technology under NCI license agreement; PDS Biotechnology accesses institute’s TARP tumor antigen technology.

Through a grant from the National Cancer Institute (NCI), Charles River Analytics is building a platform to collect and analyze biometric sensor data and connected devices used by cancer patients across the US. The goal of the project is to support large-scale population health research and to improve cancer outcomes.

NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.